EP2205566A2 - Dérives de nicotinamide. leur préparation et leur application en thérapeutique - Google Patents

Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Info

Publication number
EP2205566A2
EP2205566A2 EP08859496A EP08859496A EP2205566A2 EP 2205566 A2 EP2205566 A2 EP 2205566A2 EP 08859496 A EP08859496 A EP 08859496A EP 08859496 A EP08859496 A EP 08859496A EP 2205566 A2 EP2205566 A2 EP 2205566A2
Authority
EP
European Patent Office
Prior art keywords
pyridin
phenyl
ylmethyl
ureido
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08859496A
Other languages
German (de)
English (en)
French (fr)
Inventor
Jerôme ARIGON
Claude Bernhart
Monsif Bouaboula
Pierre Casellas
Romain Combet
Samir Jegham
Sandrine Hllalret
Pierre Fraisse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of EP2205566A2 publication Critical patent/EP2205566A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to nicotinamide derivatives, the compositions containing them and their therapeutic application, especially as anti-cancer agents.
  • the invention also relates to the process for the preparation of these compounds as well as to some of the intermediate products.
  • A denotes a carbocycle or heterocycle.
  • R 2 may especially be an aryl or alkyl group.
  • Z represents a phenyl or indanyl group and not a pyridinyl group.
  • R 13 may be a 2- or 3-pyridinyl group
  • R 4 and R 5 represent a hydrogen atom, an alkyl group , alkoxy, OH, -CF 3 or -CN.
  • a and B may each be 1, 3- or 1,4-paraphenylene or 2,4- or 2,5-thienylene
  • V is alkylene or NR 2 CO or NR 2 SO 2
  • U is alkylene group or a single bond.
  • Ring A may be substituted, more particularly with alkoxy groups or with a halogen atom.
  • These compounds all include the -CHR 2 COOR 1 motif that does not include the compounds of the invention.
  • the compounds of the invention are characterized by the presence on the ZZ 'ring of substituents A and COR 2 which is not described in WO 00/35864.
  • a halogen atom a fluorine, chlorine, bromine or iodine atom
  • An alkyl group a saturated aliphatic hydrocarbon group comprising from 1 to 6 carbon atoms (advantageously from 1 to 4 carbon atoms) linear or, when the alkyl chain comprises at least 3 carbon atoms, branched or cyclic. Mention may be made, for example, of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methylcyclopropyl, pentyl, 2,2-dimethylpropyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups. ;
  • An alkoxy group a -O-alkyl group, wherein the alkyl group is as defined above;
  • a heteroatom a nitrogen, oxygen or sulfur atom
  • a cycloalkyl group a cyclic alkyl group comprising between 3 and 8 carbon atoms, all the carbon atoms being involved in the cyclic structure.
  • An aryl group a monocyclic aromatic group, for example a phenyl group
  • a heteroaryl group a monocyclic aromatic group comprising one or more heteroatoms engaged in the cyclic structure.
  • pyridine group By way of examples, mention may be made of the pyridine group; "A heterocycloalkyl group: a cycloalkyl group as defined above, further comprising from 1 to 4 heteroatoms engaged in the ring structure.
  • tetrahydrofuranyl azetidinyl, pyrrolidinyl, piperidinyl, N-alkyl-piperidinyl, morpholinyl, piperazinyl, azepanyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl groups.
  • the present invention relates to a compound of formula (I):
  • A represents a group -NR 1 R 1 ! or (C r C 6 ) alkoxy
  • Ri and RS are such that: (i) R 1 represents: a hydrogen atom;
  • aryl group optionally substituted with one or more halogen atom (s); a heteroaryl group;
  • a (CrC 6 ) alkyl group optionally substituted with: one or more hydroxyl groups or (C 1 -C 6) alkyl groups, preferably (C 1 -C 4 ) alkoxy groups, an aryl group; (C 3 -C 6 ) cycloalkyl, a heteroaryl group, a heterocycloalkyl group or a group -NR 3 R b in which R a and R b represent, independently of one another, a hydrogen atom or a or (C 1 -C 4 ) alkyl, or together with the nitrogen atom to which they are attached form a heterocycloalkyl group optionally comprising another nitrogen atom; hydrogen or a group (CrC ⁇ Jalkyl, or
  • R 2 represents a group -QR 4 ;
  • Q represents an oxygen atom or the group -NH-.
  • R 4 represents:
  • A may represent a group -NRiR 1 'in which: (i) R 1 may be:
  • aryl group optionally substituted by one or more halogen atom (s) (preferably a fluorine atom).
  • s halogen atom
  • the aryl group may be the phenyl group;
  • a heteroaryl group such as, for example, the 3- or 4-pyridinyl group
  • a (C 3 -C 6 ) cycloalkyl group such as for example the cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group
  • (CrC 6) alkyl optionally substituted by: one or more group (s) -OH or (C 1 -C 6 JaIcOXy 1 preferably (C r C 4) alkoxy: for example methoxy, o aryl for example, phenyl group, a (C 3 -C 6 ) cycloalkyl group: for example the cyclopropyl group, a heteroaryl group: for example the pyridinyl group, in particular 2-, 3- or 4-pyridinyl group; heterocycloalkyl: for example the 2-tetrahydrofuryl group; a -NR a R b group in which R 3 and R b represent, independently of one another, a hydrogen atom or a (C 1 -C 6 ) alkyl group, preferably (C 1 -
  • R 3 and R b may be two groups (C r C 6 ) alkyl, for example two methyl groups.
  • the heterocycloalkyl formed by R a and R b can for example be the
  • R 1 from one of those described in Table I.
  • R * ! represents a hydrogen atom or a (C ⁇ CeJalkyle.
  • R 1 from any of those described in Table I. It may also choose a combination R 1 ⁇ 1 from one of those described in Table I.
  • R 1 and R'i together with the nitrogen atom to which they are attached form a group heterocycloalkyl, for example pyrrolidinyl ( N -), piperidinyl ) or
  • A may also represent a group (C 1 -C 6) alkyl, for example the ethoxy group.
  • heteroaryl group such as, for example, the pyridinyl group, in particular 2-, 3- or 4-pyridinyl;
  • a (C 3 -C 6 ) cycloalkyl group such as for example the cyclopropyl or cyclopentyl group; a (C 1 -C 6 ) alkyl group, optionally substituted by: one or more -OH or (C 1 -C 6 ) alkoxy groups, preferably (C 1 -C 4 ) alkoxy groups, for example methoxy; a heteroaryl group: for example the pyridinyl group, in particular 2-, 3- or 4-pyridinyl; a heterocycloalkyl group: for example the morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl group, more particularly by the 4-piperidinyl group; ), eg. 4-N-methyl-piperidinyl
  • the heterocycloalkyl group formed by R c and R d may be for example the pyrrolidinyl group
  • the heterocycloalkyl group formed by R 0 and R d may be optionally substituted by one or more substituents, which are identical to or different from each other when there are several of them, chosen from: -OH; (C 1 -C 4 ) alkoxy: for example methoxy; (C 1 -C 4) Alkyl: for example methyl, halogen atom: for example fluorine atom, thus substituted heterocycloalkyl
  • R 3 is in position 5 or 6 on the pyridine ring (the L group being in position 3 on this ring) as shown below: position 6 position 5
  • R 3 is even more preferentially in the 6- position.
  • R 3 represents an atom hydrogen or 5- or 6-NH 2 .
  • R 3 represents the -OH group in position 2 or 6 (see compound No. 123), the pyridine ring also exists in the 2-pyridone form: case of the -OH group in position 6
  • L may be one of those described in Table I.
  • R 1 and R 1 ! independently of one another represent a hydrogen atom or a (C 1 -C 6 ) alkyl group
  • Q is -NH-; - R 4 represents a hydrogen atom or a group ⁇ C r C 6 ) alkyl.
  • R 1 represents a group (C 1 -C 6 ) alkyl and R 1 represents a hydrogen atom or R 1 and R 1 represent two groups (C 1 -C 6 alkyl).
  • R 1 and RS represent, independently of one another, a hydrogen atom or a (C 1 -C 6 alkyl) group
  • R 4 represents a group (CrC ⁇ ) alkyl substituted with one or more -OH or (C 1 -C 6) alkyl groups, preferably (C 1 -C 4) alkyl groups, and the group -NR 0 R d in which R 0 and R d independently of one another represent a hydrogen atom or a group (C r C 6 ) alkyl or together with the nitrogen atom to which they are attached a heterocycloalkyl group selected from: pyrrolidinyl, piperidinyl, piperazinyl or N- (C 1 -C 4 ) alkylpiperazinyl, azepanyl, morpholinyl, thiomorpholinyl, 1-oxothythomorpholinyl, 1,1-dioxothiomorpholinyl, 3- or 4-hydroxy-piperidinyl, 4,4'-difluoro piperidinyl, 4-methoxy-piperidinyl, 2-methyl-pyrroli
  • R 1 represents a group (CrC 6 ) alkyl substituted with: o one or more group (s) -OH or (CrC 6 ) alkoxy, preferably (CrC 4 ) alkoxy; a group -NR a R b in which R 3 and R b represent, independently of one another, a hydrogen atom or a (C 1 -C 6 ) alkyl group, preferably (C 1 -
  • C 4 alkyl or together with the nitrogen atom to which they are attached form a heterocycloalkyl group selected from: pyrrolidinyl, piperazinyl, piperidinyl or N-fCVC-Oalkyl-piperidinyl;
  • R 4 represents a group (C r C 6 ) alkyl.
  • R a and R b may be identical and both represent a hydrogen atom or a (C 1 -C 6 ) alkyl group or may be different and represent a hydrogen atom and a (C 1 -C 6 ) alkyl group.
  • R 1 represents a group (CrC 6 ) alkyl substituted by a phenyl group or 2-, 3- or 4-pyridinyl;
  • Q is -NH-; - R 4 represents a group (CrC ⁇ Jalkyl.
  • Ri represents a (C 3 -C 6 ) cycloalkyl group
  • Q is -NH-; - R 4 represents a group (CrC 6 ) alkyl or a (C 3 -C 6 ) cycloalkyl group.
  • R 1 may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • R 4 may be cyclopropyl or cyclopentyl.
  • R 1 represents a phenyl or 3- or 4-pyridinyl group
  • RY represents a hydrogen atom
  • R 4 represents a (C 1 -C 6 ) alkyl group.
  • R 1 represents a phenyl group optionally substituted by one or more halogen atom (s);
  • Q is -NH-;
  • R 4 represents a (C 1 -C 6) alkyl group optionally substituted with the group -NR c R d in which R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl group chosen from the group pyrrolidinyl or piperidinyl.
  • R 1 and R ' 1 represent, independently of one another, a hydrogen atom or a (C 1 -C 6 ) alkyl group
  • R 4 represents a group (C r C 6 ) alkyl substituted by the 2-, 3 or 4-pyridinyl group.
  • R 1 , R 1 , R 4 are as defined above, in particular according to one of the combinations 1 to 8.
  • the compounds of the invention may exist in the form of bases or addition salts with acids. Such addition salts are also part of the invention. These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds also form part of the invention.
  • the compounds according to the invention may also exist in the form of hydrates or solvates, namely in the form of combinations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.
  • the compounds may have one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures are part of the invention.
  • the invention provides the process for preparing compounds of to the invention as well as some of the reaction intermediates.
  • a Suzuki type coupling of P 3 and P 6 is carried out .
  • HaI represents a halogen atom (chlorine, bromine, iodine).
  • the coupling is carried out in the presence of a palladium complex (in the oxidation state (O) or (N)) such as for example Pd (PPh 3 J 4 , PdCl 2 (PPh 3 J 2 , Pd (OAc) 2 , PdCl 2 (dppf) or bis (di-tert-butyl (4-dimethylaminophenyl) phosphine) dichloropalladium (II)
  • the most frequently used complexes are palladium (O) complexes, the coupling being favored in the presence of of a base, which can be for example K 2 CO 3 , NaHCO 3 , and 3 N, K 3 PO 4 , Ba (OH) 2 , NaOH, KF, CsF, Cs 2 CO 3 ...
  • the coupling can be in a mixture of an ethereal solvent and an alcohol, for example a dimethoxyethane / ethanol mixture, it can also be a toluene / water mixture (see ex.19), the temperature can be between 50.degree. and 100 ° C. More details on the Suzuki coupling, the operating conditions as well as the palladium complexes usable in: N.Miyaura and A.Suzuki, Chem. Rev. (1995), 95, 2457-2483; A.Suzuki in "Metal-catalyzed cross-coupling reactions"; Diederich, F .; Stang, PJ. Eds. Wiley-VCH: Weinhein, Germany, 1998, Chapter 2, 49-97; Littke, A. and Fu, G., Angew. Chem. Int., Ed. (1999), 38, 3387-3388.
  • K and K ' represent a hydrogen atom, an alkyl or aryl group, optionally linked together to form together with the boron atom and the two oxygen atoms a 5 to 7-membered ring.
  • one of the following groups can be used:
  • P 2 is obtained from P 1 acid by monosubstitution in position 2 with an amine of formula R 1 R 1 T NH.
  • P 1 is a 2,6-dihalogenonicotinic acid, for example 2,6-dichloronicotinic acid, which is commercially available (see Example 1).
  • the reaction can take place at room temperature and in a protic solvent such as an alcohol or water.
  • P 2 is obtained from 2,4-dihydroxy-pyrimidine-5-carboxylic acid (see ex.11). .
  • P 3 is prepared by amidification by reacting P 2 with an excess of R 4 NH 2 amine. It is advantageous to use an acid activator ("coupling agent”) such as, for example, benzotriazol-1-yloxytris (dimethylamino) -phosphonium hexafluorophosphate (or BOP, CAS:
  • an acid activator such as, for example, benzotriazol-1-yloxytris (dimethylamino) -phosphonium hexafluorophosphate (or BOP, CAS:
  • reaction is preferably carried out in the presence of a base (such as triethylamine) at room temperature, in a solvent such as tetrahydrofuran (THF) or dimethylformamide (DMF).
  • a base such as triethylamine
  • THF tetrahydrofuran
  • DMF dimethylformamide
  • the reaction is conducted in the presence of triphosgene. It is also preferably conducted in the presence of a base such as for example triethylamine and at a temperature between -5 ° C. and room temperature in an ethereal solvent such as THF.
  • A- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) -phenylamine has frequently been used for P 5 .
  • Example 8.1 presents an illustrative procedure for this reaction.
  • P 4 can be either commercial or prepared according to methods known to those skilled in the art.
  • 2-amino-5-aminomethylpyridine can also be prepared according to EP 0607804.
  • 2-amino-5-aminomethylpyridine and 6-amino-3-aminomethyl-5-methylpyridine can be prepared according to preparations D and F of EP 1050534.
  • 2-Fluoro-5-aminomethylpyridine (CAS No. 205744 -17-8) can be prepared according to Chinese Journal of Chemistry 2006, 24 (4), 521-526.
  • 5-Aminomethyl-2- (dimethylamino) pyridine (CAS No. 354824-17-2) is commercially available or can be prepared according to Journal of Agricultural and Food Chemistry 2008, 56 (1), 204-212.
  • 3-Fluoro-5-aminomethylpyridine (CAS No. 23586-96-1) and 2-fluoro-3-aminomethylpyridine can be prepared according to WO 2005066126 (preparations 46 and 47).
  • 2-Amino-3-methyl-5-aminomethylpyridine (CAS No.
  • Esterification is known to those skilled in the art and consists in reacting the acid function of P 2 or P 8 with the alcohol function of R 4 OH in the presence of a strong acid as a catalyst (Practical Organic Chemistry AI Vogel 3rd ed. page 382) or of an acid activator such as EDCI.
  • P 10 can be either commercial or prepared according to methods known to those skilled in the art.
  • trans-3- (3-pyridyl) acrylic acid is marketed by Sigma-Aldrich.
  • P 10 can also be prepared according to J.Org.Chem. 1998, 63, 8785-8789 from the ⁇ - corresponding formylpyridine.
  • P 12 can be either commercial or prepared according to methods known to those skilled in the art. For example, 3- (3-pyridinyl) propanoic acid is marketed by Sigma-Aldrich. P 12 can also be prepared by hydrogenation of P 10 (Journal of Medicinal Chemistry 1993, 36 (22), 3293-9).
  • P 13 can be obtained according to Scheme 6.
  • the amidation by R 4 NH 2 can be carried out in presence of an acid activator such as, for example, N, N'-carbonyl diimidazole (CDI) (see: R. Paul, GW Anderson (1960).) N.N'-Carbonyldiimidazole, a New Peptide Forming Reagent ', Journal of the American Chemical Society 82: 4596-4600).
  • the reaction may be conducted in a solvent such as THF. We can take inspiration from the conditions of ex.10.1.
  • the next step is performed in the presence of the alcoholate R ⁇ O ".
  • the reaction may be carried out in THF at a temperature of about 70 0 C. It will be guided by conditions ex.10.2 .
  • a protecting group to protect one or more chemical function (s), including a primary or secondary amine function.
  • PG protecting group
  • R c and R d both represent a hydrogen atom
  • the amidification of Scheme 2 is carried out using for R 4 NH 2 the compound 2 HN- (C r )
  • the function (s) is / are then obtained (s) by a deprotection step (final or intermediate) whose conditions depend on the nature of the function (s) protected (s) and protective group used.
  • the deprotection step is carried out in an acid medium using, for example, HCl or triflic acid. This gives the corresponding salt (hydrochloride or triflate) if appropriate; see compounds No. 5, 32, 94, 104, 119.
  • Another method of obtaining salts is to contact the compound in its base form with the acid.
  • the starting compounds and the reagents when their method of preparation is not described, are commercially available or described in the literature, or they can be prepared according to methods described therein or which are known to those skilled in the art. Those skilled in the art may also be inspired by the operating conditions given in the examples which are described below.
  • the invention relates to a pharmaceutical composition comprising a compound as defined above in combination with a pharmaceutically acceptable excipient.
  • the excipient is selected from the usual excipients known to those skilled in the art according to the pharmaceutical form and the desired mode of administration.
  • the mode of administration can be, for example, orally or intravenously.
  • the invention relates to a medicament which comprises a compound as defined above and the use of a compound as defined above for the manufacture of a medicament. It can be useful for treating a pathological condition, especially cancer. This drug may find use in therapy, particularly in the treatment or prevention of diseases caused or exacerbated by the proliferation of cells and in particular tumor cells.
  • the drug (as well as a compound according to the invention) can be administered in combination with one (or more) anticancer agents, in particular chosen from: "chemotherapy agents such as alkylating agents, platinum derivatives, antibiotic agents, antimicrotubule agents, taxoids, anthracyclines, group I and II topoisomerase inhibitors, fluoropyrimidines, cytidine analogues, adenosine analogs, enzymes, as well as estrogenic and androgenic hormones; • antivascular or anti-angiogenic agents.
  • chemotherapy agents such as alkylating agents, platinum derivatives, antibiotic agents, antimicrotubule agents, taxoids, anthracyclines, group I and II topoisomerase inhibitors, fluoropyrimidines, cytidine analogues, adenosine analogs, enzymes, as well as estrogenic and androgenic hormones; • antivascular or anti-angiogenic agents.
  • a treatment with radiation.
  • This treatment can be administered simultaneously, separately or sequentially.
  • the treatment will be adapted by the practitioner according to the patient and the tumor to be treated.
  • the invention also relates to a method of treatment of pathologies indicated above which comprises administering to a patient an effective dose of a compound of the invention or a pharmaceutically acceptable salt or hydrates or solvates.
  • the following examples illustrate the preparation of certain compounds according to the invention. These examples are not limiting and only illustrate the present invention.
  • the numbers of the compounds exemplified refer to those given in the table below, which illustrates the chemical structures and the physical properties of some compounds according to the invention.
  • the compounds were analyzed by HPLC-UV-MS coupling (liquid chromatography, ultraviolet (UV) detection and mass detection).
  • the device used consists of an Agilent chromatographic chain equipped with an Agilent diode array detector and a ZQ Waters single quadrupole mass spectrometer or a Quattro-MicroWaters triple quadrupole mass spectrometer.
  • the liquid chromatography / mass spectrometry (LC / MS) spectra were recorded in electrospray (ESI) positive mode, in order to observe the ions resulting from the protonation of analyzed compounds (MH + ) or the formation of adducts with other cations such as Na + , K + , etc.
  • the ionization parameters are as follows: cone voltage: 20 V; capillary voltage: 3 kV; source temperature: 120 ° C. desolvation temperature: 450 ° C; gas desolvation: N 2 to 450 Uh.
  • HPLC conditions are chosen from one of the following methods:
  • Example 11 4-Ethylamino-2- [4- (3-pyridin-3-ylmethyl-ureido) -phenyl] -pyrimidine-5-carboxylic acid (2-piperidin-1-yl-ethyl) -amide (compound no. 80) 11.1. 2,4-dichloro-pyrimidine-5-carbonyl chloride
  • Example 12 6- ⁇ 4- [3- (6-amino-pyridin-3-ylmethyl) -ureido] -phenyl ⁇ -2-ethylamino-N- (2-piperidin-1-yl-ethyl) -nicotinamide (compound No. 81) 12.1. 6-Chloro-2-ethylamino-N- (2-piperidin-1-yl-ethyl) -nicotinamide
  • Example 14 2- (Cyclopropylmethylamino) -N-methyl-6- [4- (3-pyridin-3-ylmethyl-ureido) phenyl] -nicotinamide (Compound No. 48)
  • Example 17 2- (2-Methoxy-ethylamino) -N-methyl-6- [4- (3-pyridin-3-ylmethyl-ureido) - phenyl] -nicotinamide (compound 51)
  • Example 19 4 '- [3- (6-Amino-pyridin-3-ylmethyl) -ureido] -3-ethylamino-biphenyl-4-carboxylic acid (2-piperidin-1-yl-ethyl) -amide (compound no.
  • the medium is stirred for 30 min at room temperature and under argon, and then 0.034 g (0.05 mmol) of bis (di-tert-butyl (4-dimethylaminophenyl) phosphine) dichloropalladium (II) are added.
  • the reaction medium is stirred under reflux and under argon for 5 h.
  • the solvent is evaporated under reduced pressure.
  • the residue is taken up in dichloromethane, washed successively with water and saturated NaCl solution and the organic phase is dried over sodium sulphate.
  • nBu n-butyl
  • tBu tert-butyl
  • iPr isopropyl for R3: 6-NH 2 means -NH 2 at the 6-position on the pyridine ring as indicated; 2-F means -F in position 5 on the pyridine ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP08859496A 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique Withdrawn EP2205566A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique
PCT/FR2008/001338 WO2009074749A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
EP2205566A2 true EP2205566A2 (fr) 2010-07-14

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08859496A Withdrawn EP2205566A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Country Status (19)

Country Link
US (1) US20100222319A1 (https=)
EP (1) EP2205566A2 (https=)
JP (1) JP2010540504A (https=)
KR (1) KR20100065165A (https=)
CN (1) CN101808996A (https=)
AR (1) AR066171A1 (https=)
AU (1) AU2008334457A1 (https=)
BR (1) BRPI0817973A2 (https=)
CA (1) CA2700559A1 (https=)
CL (1) CL2008002893A1 (https=)
FR (1) FR2921657A1 (https=)
IL (1) IL204663A0 (https=)
MX (1) MX2010003445A (https=)
PA (1) PA8797301A1 (https=)
PE (1) PE20091033A1 (https=)
RU (1) RU2010116765A (https=)
TW (1) TW200918056A (https=)
UY (1) UY31367A1 (https=)
WO (1) WO2009074749A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
JP7092356B2 (ja) * 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
AU2020378067A1 (en) * 2019-11-06 2022-05-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
CZ20012185A3 (cs) * 1998-12-16 2001-10-17 Bayer Aktiengesellschaft Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009074749A2 *

Also Published As

Publication number Publication date
AU2008334457A1 (en) 2009-06-18
WO2009074749A2 (fr) 2009-06-18
WO2009074749A3 (fr) 2009-08-20
CN101808996A (zh) 2010-08-18
RU2010116765A (ru) 2011-11-27
PA8797301A1 (es) 2009-05-15
FR2921657A1 (fr) 2009-04-03
MX2010003445A (es) 2010-04-27
CA2700559A1 (fr) 2009-06-18
PE20091033A1 (es) 2009-08-17
US20100222319A1 (en) 2010-09-02
UY31367A1 (es) 2009-04-30
CL2008002893A1 (es) 2009-10-16
KR20100065165A (ko) 2010-06-15
IL204663A0 (en) 2010-11-30
AR066171A1 (es) 2009-07-29
JP2010540504A (ja) 2010-12-24
BRPI0817973A2 (pt) 2019-04-09
TW200918056A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
EP2205566A2 (fr) Dérives de nicotinamide. leur préparation et leur application en thérapeutique
EP2411368A1 (fr) Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
EP3224252B1 (en) Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii
CA2690337C (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
US20130029961A1 (en) Substituted Heterocyclic Aza Compounds
CN111484491B (zh) 取代吡啶并环化合物、其制备方法和用途
CN115210233A (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
EP2755952B1 (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
JPH06506956A (ja) ピリドンの新規な誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
EP2627637B1 (en) N-pyridin-3-yl or n-pyrazin-2-yl carboxamides
JP2008516976A (ja) 抗増殖活性を有するインダンアミド
MX2013011253A (es) Derivados de 3-ureidoisoquinolin-8-ilo.
FR2943675A1 (fr) Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670A1 (fr) Derives anticancereux,leur preparation et leur application en therapeutique
WO2026090477A1 (en) Helicase inhibitors and uses thereof
JP2024544556A (ja) Ｄｒａｋ２阻害剤およびその製造方法と使用
CN116655518A (zh) 一种靛红衍生物及其制备方法和应用
FR2965263A1 (fr) Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
HK1145491A (zh) 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用
CN104098574A (zh) 氮杂环丁烷取代嘧啶类化合物及其用途
HK1193598A (en) 5-cycloalkyl-or 5-heterocyclyl-nicotinamides
JPH0441143B2 (https=)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

17Q First examination report despatched

Effective date: 20120419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120830